Verrica PharmaceuticalsVRCA
VRCA
About: Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
Employees: 71
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
22% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 18
18% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 17
1% more funds holding
Funds holding: 79 [Q3] → 80 (+1) [Q4]
3% less capital invested
Capital invested by funds: $21.6M [Q3] → $20.9M (-$638K) [Q4]
1.86% less ownership
Funds ownership: 34.91% [Q3] → 33.05% (-1.86%) [Q4]
50% less call options, than puts
Call options by funds: $2K | Put options by funds: $4K
Research analyst outlook
We haven’t received any recent analyst ratings for VRCA.
Financial journalist opinion
Neutral
GlobeNewsWire
5 days ago
Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025
WEST CHESTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m.
Neutral
GlobeNewsWire
1 week ago
Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York
WEST CHESTER, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Citizens Life Sciences Conference in New York City.
Neutral
GlobeNewsWire
1 month ago
Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors
WEST CHESTER, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Gavin Corcoran, M.D.
Positive
Zacks Investment Research
1 month ago
Here's Why Verrica Pharmaceuticals (VRCA) Is a Great 'Buy the Bottom' Stock Now
Verrica Pharmaceuticals (VRCA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Neutral
GlobeNewsWire
1 month ago
Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
WEST CHESTER, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference.
Neutral
GlobeNewsWire
1 month ago
Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D.
WEST CHESTER, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Noah L. Rosenberg, M.D., as Chief Medical Officer.
Neutral
Seeking Alpha
2 months ago
Verrica Pharmaceuticals, Inc. (VRCA) Q4 2024 Earnings Conference Call Transcript
Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA ) Q4 2024 Earnings Conference Call March 10, 2025 4:30 PM ET Company Participants John Fraunces - Director, Corporate Communications, LifeSci Advisors, IR Jayson Rieger - President and CEO John Kirby - Interim CFO Conference Call Participants Stacy Ku - TD Cowen Gregory Renza - RBC Capital Markets Kemp Dolliver - Brookline Capital Markets Operator Good evening, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals' Fourth Quarter and Full Year 2024 Corporate Update Conference Call. At this time, all participants are in a listen-only mode.
Negative
Zacks Investment Research
2 months ago
Verrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue Estimates
Verrica Pharmaceuticals Inc. (VRCA) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.48 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
– Company generated quarterly sequential growth in YCANTH® dispensed applicator units of 12.3% in Q4'24 concurrent with significantly lower operating expenses –
Neutral
GlobeNewsWire
2 months ago
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025
WEST CHESTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m.
Charts implemented using Lightweight Charts™